Stephen A. Strickland

Hematology
2410 Patterson St
Ste 500
Nashville, TN 37203

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood
Published: March 18, 2026

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Journal: Blood
Published: February 20, 2026

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Journal: Blood
Published: February 20, 2026

Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).

Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).

Journal: Leukemia & lymphoma
Published: November 12, 2025

Antibody-drug conjugates in hematologic malignancies.

Antibody-drug conjugates in hematologic malignancies.

Journal: Cancer
Published: October 08, 2025

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Journal: Blood
Published: September 19, 2025

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Journal: Blood
Published: September 19, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Journal: Blood advances
Published: May 06, 2025

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.

Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.

Journal: Blood neoplasia
Published: April 07, 2025

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Journal: JCO oncology practice
Published: March 20, 2025
Showing 1-12 of 65

Last Updated: 09/26/2026